The 3P Project for a one month or less treatment for TB that works for everyone, everywhere.

3P
PUSH • PULL • POOL
Better TB treatment. Faster.
Drug resistant TB Treatment

“To hell with TB; I’ve had enough. If you try to make it nice instead of saying it straight, people easily ignore it… It took my hearing away, now it wants to take my life…”

- Phumeza, 22 years old, diagnosed with XDR-TB in June 2010
Countries that had notified at least one case of extensively drug-resistant tuberculosis by the end of 2012

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

© WHO 2013. All rights reserved.
The case for action is clear

- Funding levels for R&D need to increase overall
- The current incentive structures do not deliver for TB
- New, well targeted incentives must be put in place to:
  - bring new researchers and developers to the problem
  - re-engage traditional investors
  - ensure a healthy drug development pipeline
  - create an open collaborative framework that enables several drugs to be developed in parallel as \textit{combination} regimens
The 3P project

A new way of doing science with the patient at its core.

Rewarding the best science, ensuring collaboration so treatments that work for all are developed quickly.

The ‘3P project’ will deliver a one month or less cure for TB that works for everyone, everywhere.
3Ps: Push + Pull + Pool

A mix of incentives & managing and sharing of IP:

- **PUSH** funding to finance R&D activities upfront (i.e. through grants)

- **PULL** funding to incentivise R&D through financial rewards on achieving objectives (i.e. milestone prizes)

- **POOL** of IP and data for open collaborative research and fair licensing for affordable products
R&D Financing Structure

**Legend**
- Various TB Compounds
- Milestone Prize
- Grant funding

Large Milestone Prize for compounds entering the pool for clinical development (Phase I)

Grant funding for regimen trials (phases I – III) from existing and new sources

**Discovery**
- Hit to Lead
- Pre-clinical Studies

**Later Stage Preclinical**
- GLP Tox

**Clinical Development**
- Phase I
- Phase II
- Phase III
The 3P Project

The ‘3P project’ will deliver a one month or less cure for TB that works for everyone, everywhere.

Using innovative funding strategies to incentivise collaborative research

– Awarding prize money for promising new TB drugs at an early stage

– facilitating the early sharing of clinical data and intellectual property so that promising candidates can easily be combined

– Offering grant-based funding to pay for clinical trials in new treatment regimens

For more information:

http://www.msfaccess.org/spotlight-on/3p-project-new-approach-developing-better-treatments-tb
Benefits of 3P over current model

This framework offers four benefits over the current system:

1) reduces the duplication of research efforts thereby saving time and money
2) “de-risks” potential combinations as early and as affordably as possible
3) accelerates drug combination development
4) reduces the risk of resistance to new compounds
Organisational Chart

Permanent observer

WHO

Steering Committee

Observer

TBA, MSF, STBP, CS, SAG (Chair)

MPP, C-PATH, IRC-SA

PROJECT MANAGEMENT
PRINCIPLE FUNDING RECIPIENT
DONOR MANAGEMENT
GRANT & PRIZE MAKING BODY

The UNION

SCIENTIFIC ADVISORY COMMITTEE

IP LICENSING FOR INNOVATION & ACCESS

MPP

ADVOCACY COMMUNICATION STAKEHOLDERS RESOURCE MOBILIZATION

STBP

DATA POOLING

C-PATH

VIRTUAL SECRETARIAT